Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of May 2022, with the report signed on May 11, 2022. The registrant is a foreign private issuer incorporated under the laws of the British Virgin Islands, with its principal executive office located in Taizhou, Jiangsu, China.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the departure of a senior officer:
- Officer: Mr. Jingzhen Deng, Chief Scientific Officer and Chief Operation Officer.
- Effective Date: December 15, 2021.
- Reason: Personal reasons.
- Context: The resignation was not the result of any disagreements with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on market conditions, or specific risk factors beyond the disclosed officer departure.
Investor Verification Checklist
- Verify the current status of the Chief Scientific Officer and Chief Operation Officer roles following Mr. Deng's resignation.
- Confirm whether a successor has been appointed for the departed executive positions.
- Review subsequent filings to assess any operational impact resulting from the leadership change.